Skip to main content

Table 5 Complications of high-risk patients undergone different treatment

From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

Adverse Effects

MAB+EBRT

%(n=117)

MAB+EBRT+PPB

%(n=203)

χ ²

P Value

Acute Urology Function

 ABS Grade 0

12.82

5.42

5.447

0.020

 ABS Grade 1

48.72

25.12

18.480

0.000

 ABS Grade 2

20.51

31.53

4.516

0.034

 ABS Grade 3

5.13

23.15

17.449

0.000

 ABS Grade 4

12.82

14.78

0.235

0.628

Late Urology Function

 Urgent/Incontinence

1.71

1.48

0.026

0.872

 Hesitancy/Retention

1.71

3.45

0.821

0.365

 Gross Hematuria

4.27

6.4

0.635

0.426

 Stricture

0

0.49

0.578

0.447

 Frequency/Nocturia

15.38

25.12

4.162

0.041

Acute Gastrointestinal Function

 RTOG Grade 0

90.6

88.67

0.291

0.590

 RTOG Grade 1

5.13

5.91

0.086

0.769

 RTOG Grade 2

3.42

3.45

0.000

1.000

 RTOG Grade 3

0.85

1.97

0.601

0.438

 RTOG Grade 4

0

0

——

——

Late Gastrointestinal Function

 Diarrhoea

21.37

13.3

3.549

0.060

 Nausea/Vomiting

7.69

4.93

1.017

0.313

 Abdominal Pain

4.27

3.94

0.021

0.885

 Rectal Bleeding

5.13

10.34

2.614

0.106

 Intestinal Fistula

0

0.49

0.578

0.447

Endocriology Function

 Breast Pain

69.23

63.05

1.250

0.264

 Xerosis Cutis

11.11

19.7

3.966

0.046

 Hot Flush

20.51

37.44

9.897

0.002

 Sexual Dysfunction

53.85

47.78

1.091

0.296

Other System Function

 Liver Dysfunction

5.13

8.37

1.172

0.279

 Renal Dysfunction

7.69

6.4

0.192

0.661

 Angina Pectoris

34.18

25.12

2.997

0.083

 Heart Failure

7.69

2.96

3.727

0.054

 Dyspnea

3.42

0.99

2.389

0.122

 Anaemia(moderate/severe)

16.24

16.75

0.014

0.906

  1. Note: ABS American Brachytherapy Society, RTOG Radiation Therapy Oncology Group